Dr. Bishwajit Nag is the Founder and current CEO of NRL where he is involved in developing new generation of biotechnology research products for proteomics, genomics and immunology. Prior to that, he was the Founder and CEO of BEXEL Pharmaceuticals Inc., CA, (2002-2007), a joint venture drug discovery company in partnership with Orchid Chemicals

Bishwajit Nag, Founder & CEO

Dr. Bishwajit Nag is the Founder and current CEO of NRL where he is involved in developing new generation of biotechnology research products for proteomics, genomics and immunology. Prior to that, he was the Founder and CEO of BEXEL Pharmaceuticals Inc., CA, (2002-2007), a joint venture drug discovery company in partnership with Orchid Chemicals & Pharmaceuticals of Chennai, India, where he also served as Orchid’s board of director from 2002-2007. From 1996-2000 Dr. Nag served as the founder and chief scientific officer (CSO) at Calyx Therapeutics Inc., CA, a technology based small molecule drug discovery company for the treatment of Diabetes and Inflammation.

He served as the Director of Research & Development at Anergen Inc. from 1988-1995, a NASDAQ-listed corporation (symbol: ANRG) later acquired by Corixa Corporation of Seatle, WA.  At Anergen, he was involved in developing recombinant proteins based biologicals for the treatment of a number of autoimmune diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), Type I diabetes and myasthenia gravis (MG) in collaboration with Novo-Nordisk, Ekzo-Nobel and Zymogenetics Inc.  Before joining Anergen Inc., Dr. Nag served as a senior scientist in the development of the recombinant tissue plasminogen activator (TPA) at Berlex Biosciences in collaboration with Abbott Laboratories.

Dr. Nag received his B.Sc. with Honors in 1977 (Biology/Chemistry), M.Sc. Biochemistry in 1979 and Ph.D. in Biochemistry in 1984 from Banaras Hindu University, India.  Dr. Nag’s Ph.D. dissertation was carried out in close association with Late Prof. D.P. Burma and Late Noble Laureate Dr. Severo Ochoa, where his focus was involved in ribosomal RNAs and mechanism of protein synthesis.  From 1984 to 1986, he was the NIH post-doctoral fellow at Biological Chemistry Department, University of California, Davis, CA with Prof. Robert R. Traut where he was involved in developing over 20 different monoclonal antibodies against ribosomal proteins. Dr. Nag has established extensive scientific collaborations with Stanford University CA, University of California Los Angeles, Kennedy Institute of Rheumatology London, Max-Plank Institute Germany and Vanderbilt University, Nashville TN during his 25 years of career.  Dr. Nag’s diverse experience of exclusive new drug discovery include recombinant proteins, monoclonal antibodies, small molecules and natural product based rationally designed molecules.

Dr. Nag held several board of directors positions such as Lablogix Inc., USA (1992-1996), Calyx Therapeutics Inc., USA (1996-2000), BEXEL Pharmaceuticals Inc., USA (2002-2007), BEXEL Biotechnology Inc., USA (1996-2007), Orchid Chemicals & Pharmaceuticals Ltd., India (2002-2007) and Orchid Research Laboratories Ltd., India (2005-2007).  His scientific entrepreneurship and business experience include: Launching technology based companies, Raising venture capital funds, Developing drugs from discovery to Phase II clinical trials, Filing INDs with US-FDA and European regulatory agencies, Licensing new drugs to major pharmaceuticals companies, IPO-listing to NASDAQ, Merger and Acquisitions.

Dr. Nag has authored over 200 peer-reviewed scientific publications/abstracts and is an inventor of over 100 US and international patents in the field of biotechnology, molecular biology and new drug discoveries.  He has received several international honors and awards during his career including American Medal of Honor in 2001 and United States National Leadership award in 2003 from the President of the United States.